Eledon Pharmaceuticals, Inc. announced on August 11, 2025, that it will restate several previously issued financial statements due to errors in accounting for its Preferred Stock classification. This restatement will not affect the company's cash position or operations, but indicates a material weakness in their financial reporting controls, requiring amendments to filings for the fiscal years ended December 31, 2023 and 2024.